Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therapeuti ...

Exhibit 99.1 vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. – May 9, 2024 – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments. "The first quarter of 2024 saw us reach several ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU ...

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update HIGH POINT, N.C. – March 13, 2024 – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments. "We made important progress ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therap ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therapeutic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therapeuti ...

Research and Development - The company has incurred approximately $612.5 million in research and development expenses since inception, with $12.4 million spent in 2022 alone[296]. - Research and development expenses for TTP399 increased from $917,000 in 2020 to $9.6 million in 2022, reflecting a significant investment in this lead program[296]. - The company anticipates significant ongoing research and development expenses as it advances TTP399 and other drug candidates[296]. - Major components of research and development costs include clinical trials, drug development, and regulatory compliance, which are expensed as incurred[340]. Clinical Trials and Regulatory Strategy - The company plans to conduct two pivotal clinical trials for TTP399, recruiting around 1,000 patients, with the primary endpoint being the difference in hypoglycemia events between treatment and placebo groups[286][287]. - TTP399 received Breakthrough Therapy Designation from the FDA, which may expedite its development and review timelines[289]. - The company has engaged with the FDA on optimal clinical trial designs for TTP399, indicating proactive regulatory strategy[286]. Financial Performance - Revenue for the year ended December 31, 2022, was $2.0 million, a decrease of 49.8% from $4.0 million in 2021[308]. - Research and development expenses decreased by approximately $1.0 million, or 7.3%, from $13.3 million in 2021 to $12.4 million in 2022[309]. - General and administrative expenses slightly decreased by $0.1 million, or 1.2%, from $12.3 million in 2021 to $12.2 million in 2022[310]. - The net loss attributable to vTv Therapeutics Inc. increased to $19.2 million in 2022 from $13.0 million in 2021, representing a decline of 47.7%[307]. - As of December 31, 2022, the company had cash and cash equivalents of $12.1 million and an accumulated deficit of $265.5 million[314]. Funding and Capital Requirements - The company entered into a $25 million investment agreement with G42 Investments, selling shares at $2.41 each, with potential additional shares contingent on FDA approval of TTP399[290]. - A $10 million investment was secured from CinPax, with shares sold at approximately $2.41 each, and additional warrants issued contingent on FDA approval of TTP399[291]. - The company anticipates needing substantial additional funding to continue operations and clinical trials, with ongoing evaluations of financing strategies[327]. - The company expects to finance cash needs through equity offerings, debt financings, and collaborations until substantial revenue from drug sales is generated[330]. - Additional capital raised through equity or convertible debt may dilute existing common stockholders' interests and impose restrictions on company actions[331]. - The company has sold $31.2 million worth of Class A common stock under the ATM Offering, leaving $37.3 million available for future sales[316]. - The company received proceeds of $12.0 million from the G42 promissory note on February 28, 2023, to support liquidity[328]. Future Outlook - The company expects revenue generation to fluctuate based on the timing of license fees, milestone payments, and product sales[294]. - The company expects to continue incurring losses for the foreseeable future as it progresses with clinical trials and seeks regulatory approvals[314]. - Future capital requirements will depend on various factors, including the progress and costs of clinical trials for TTP399, a potential therapy for type 1 diabetes[329]. Tax and Market Risk - The company recognizes deferred tax assets and liabilities based on differences between financial reporting and tax bases, considering future taxable income and tax planning strategies[346]. - Share-based compensation expense is based on the fair value of awards at grant date, estimated using the Black-Scholes option pricing formula[350]. - The company has limited exposure to market risk, with cash and cash equivalents maintained in high credit quality financial institutions[353]. - There is no material foreign currency exposure affecting the company's financial position[354].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therap ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therapeutic ...